Barbara Ryan Deutsche Bank on Biotech Stocks

Barbara Ryan, senior analyst of Deutsche Bank commented on MERCK (NYSE:MRK) and Pfizer (NYSE:PFE) today on CNBC

lower side effect formulation of niacin will be filed FDA next year, combining with generic Zocor delayed

three things driving perfomance of biotech stocks:
(1) oversold position
(2) aggressive restructuring
(3) improving product portfolio

FDA is conservative right now, but when you have unique product that fills void, gets approved quickly:

(1) first inhaled insulin Exubera approved for Pfizer
(2) Gardisil, vaccine to prevent cervical cancer approved for Merck